Clinical Scientific Director at Novartis
East Hanover, New Jersey
Novartis
Clinical Scientific Director
September 2015 to Present
Novartis
Clinical Scientific Associate Director
May 2014 to August 2015
Novartis
Medical Specialist
March 2012 to May 2014
Novartis
Clinical Research Medical Advisor
January 2012 to February 2012
São Paulo Area, Brazil
Novartis
Medical Advisor/ LACAN Clinical Expert
March 2009 to January 2012
São Paulo Area, Brazil
Aché Laboratórios Farmacêuticos S.A.
Clinical Research Medical Manager
March 2008 to March 2009
Aché Laboratórios
Medical Advisor/Medical Manager Neurosciences
April 2006 to March 2008
Aché Laboratórios
Medical Trainee - Aché Laboratórios Farmacêuticos S.A.
September 2006 to May 2007
Greenline Saúde
Emergence Room Physician
January 2006 to August 2006
São Paulo Area, Brazil
Força Aerea Brasileira
2nd Lieutenant (Medical Officer)
January 2005 to January 2006
Guaratinguetá Area, Brazil
Hospital Beneficente Santa Lídia
Critical Care Unit Physician
August 2003 to December 2004
Ribeirão Preto Area, Brazil
Hospital Santa Casa de Misericórdia de Araraquara
Emergence Room Physician
January 2003 to December 2004
Prefeitura Municipal de Sertãozinho
General Practice Physician
January 2003 to July 2003
Universidade Estadual de Campinas
PhD Pharmacology
2009 to 2011
Universidade Estadual de Campinas
MSc Pharmacology
2008 to 2009
CETRUS
Echocardiography (Informal Training) Ecocardiography
2006 to 2006
Brazilian Air Force
2nd Lieutenant Medical Officer
2005 to 2006
Santa Casa de Misericórdia de Ribeirão Preto
Post-graduation - Residency Clinical Cardiology
2003 to 2005
Universidade Estadual de Campinas
M.D. Medicine
1997 to 2002
Cardiovascular Metabolism (CVM) Franchise (Serelaxin - Acute Decompensated Heart Failure) - Medical Lead for RELAX-AHF-2. The purpose of the study is to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients. More information: http://www.clinicaltrials.gov/ct2/show/NCT01870778?term=serelaxin&rank=2 Cardiovascular Metabolism (CVM) Franchise (Serelaxin - Acute Decompensated Heart Failure) - Medical Lead for RELAX-AHF-2. The purpose of the study is to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients. More information: http://www.clinicaltrials.gov/ct2/show/NCT01870778?term=serelaxin&rank=2
What company does Leandro Boer Martins, MD PhD work for?
Leandro Boer Martins, MD PhD works for Novartis
What is Leandro Boer Martins, MD PhD's role at Novartis?
Leandro Boer Martins, MD PhD is Clinical Scientific Director
What industry does Leandro Boer Martins, MD PhD work in?
Leandro Boer Martins, MD PhD works in the Pharmaceuticals industry.
📖 Summary
Medical Director (Cardiology - MD, Pharmacology - PhD) with 9 years of experience on Medical Affairs and Clinical Development. Publication citations: http://scholar.google.com.br/citations?user=Usa2b4wAAAAJ&hl=pt-BRClinical Scientific Director @ Cardiovascular Metabolism (CVM) Franchise (Serelaxin - Acute Decompensated Heart Failure) - Medical Lead for RELAX-AHF-2. The purpose of the study is to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients. More information: http://www.clinicaltrials.gov/ct2/show/NCT01870778?term=serelaxin&rank=2 From September 2015 to Present (4 months) Clinical Scientific Associate Director @ Cardiovascular Metabolism (CVM) Franchise (Serelaxin - Acute Decompensated Heart Failure) - Medical Lead for RELAX-AHF-2. The purpose of the study is to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients. More information: http://www.clinicaltrials.gov/ct2/show/NCT01870778?term=serelaxin&rank=2 From May 2014 to August 2015 (1 year 4 months) Medical Specialist @ June 2013 - Current date: Critical Care Franchise (Serelaxin - Acute Decompensated Heart Failure) The purpose of the study is to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients. More information: http://www.clinicaltrials.gov/ct2/show/NCT01870778?term=serelaxin&rank=2 March 2012 - June 2013: Established Medicines Development Franchise.Working on the clinical trial program which provides new safety data for long-acting inhaled asthma medications called Long-Acting Beta Agonists (LABAs). More information: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm From March 2012 to May 2014 (2 years 3 months) Clinical Research Medical Advisor @ Medical Scientific Support for ICRO (International Clinical Research Operations), DS&E (Drug Safety and Efficacy) and NPP (New Products Planning). From January 2012 to February 2012 (2 months) São Paulo Area, BrazilMedical Advisor/ LACAN Clinical Expert @ Cardiovascular & Metabolism Franchise - Rasilez/Tekturna (aliskiren) and Established Medicines (AI) Medical Advisor From March 2009 to January 2012 (2 years 11 months) São Paulo Area, BrazilClinical Research Medical Manager @ Medical writing and support for phase III-IV multicenter national trials. Member of the New Products Committee. From March 2008 to March 2009 (1 year 1 month) Medical Advisor/Medical Manager Neurosciences @ Medical affairs activities for antidepressants, antipsychotics, anxiolytics and migrania marketed drugs. From April 2006 to March 2008 (2 years) Medical Trainee - Aché Laboratórios Farmacêuticos S.A. @ 1st group of trainees of the company. From September 2006 to May 2007 (9 months) Emergence Room Physician @ From January 2006 to August 2006 (8 months) São Paulo Area, Brazil2nd Lieutenant (Medical Officer) @ Cardiologist of the Brazilian Air Force From January 2005 to January 2006 (1 year 1 month) Guaratinguetá Area, BrazilCritical Care Unit Physician @ From August 2003 to December 2004 (1 year 5 months) Ribeirão Preto Area, BrazilEmergence Room Physician @ From January 2003 to December 2004 (2 years) General Practice Physician @ From January 2003 to July 2003 (7 months) PhD, Pharmacology @ Universidade Estadual de Campinas From 2009 to 2011 MSc, Pharmacology @ Universidade Estadual de Campinas From 2008 to 2009 Echocardiography (Informal Training), Ecocardiography @ CETRUS From 2006 to 2006 2nd Lieutenant, Medical Officer @ Brazilian Air Force From 2005 to 2006 Post-graduation - Residency, Clinical Cardiology @ Santa Casa de Misericórdia de Ribeirão Preto From 2003 to 2005 M.D., Medicine @ Universidade Estadual de Campinas From 1997 to 2002 Leandro Boer Martins, MD PhD is skilled in: Clinical Trials, Pharmacovigilance, Medical Affairs, Pharmaceutical Industry, Clinical Research, Drug Development, Clinical Pharmacology, ICH-GCP, Clinical Cardiology, Reference Manager, Medicine, Medical Writing, Pharmacology, EndNote X4
Extraversion (E), Sensing (S), Feeling (F), Judging (J)
1 year(s), 3 month(s)
Unlikely
Likely
There's 71% chance that Leandro Boer Martins, MD PhD is seeking for new opportunities
Issued by State University of Campinas - UNICAMP · December 2002
Issued by Novartis Pharmaceuticals Corporation · September 2012
Enjoy unlimited access and discover candidates outside of LinkedIn
Trusted by 400K users from
76% of Fortune 500 companies
The most accurate data ever
Hire Anyone, Anywhere
with ContactOut today
Making remote or global hires? We can help.
No credit card required